API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.europeanpharmaceuticalreview.com/news/176282/minoryx-and-neuraxpharm-therapy-for-rare-cns-disorders/
https://www.pharmiweb.com/press-release/2022-09-20/minoryx-s-marketing-authorization-application-for-its-lead-candidate-leriglitazone-validated-by-ema-for-orphan-indication-x-linked-adrenoleukodystrophy-x-ald
https://www.pharmiweb.com/press-release/2021-01-26/minoryx-presents-topline-results-from-phase-23-advance-study-demonstrating-significant-clinical-benefit-of-leriglitazone-in-adrenomyeloneuropathy
https://www.eib.org/en/press/all/2020-296-eib-provides-minoryx-with-up-to-eur25-million-to-support-development-of-breakthrough-therapies-in-orphan-neurodegenerative-diseases
https://en.prnasia.com/releases/global/minoryx-therapeutics-and-sperogenix-therapeutics-enter-into-an-exclusive-license-agreement-to-develop-and-commercialize-leriglitazone-in-mainland-china-hong-kong-and-macau-292572.shtml